Hey bass, there was no angle or spin, imo, done by ACA, they simply were running a story, asked for by OBJ, to promote the miracle wand.
Thru lack of foresight (?), by OBJ, (why did the company not request a month trial, cohort of say five people, and application of product strictly followed), they embarrassed themselves, imo.
Blame OBJ not ACA, after so much hype on getting a gig it end up flying like a lead balloon, thank goodness the Olay cream presented extremely well.
See what happens, it is already days old news, proof of the pudding, ultimately, will be determined by resulting sales and then revenue down the track.
ACA outcome is largely irrelevant , what happens in Asia, States etc is absolutely relevant to OBJ success.
Regards to info and transparency from the company ... watch what you wish for, if there was true transparency done of us would have bought in yet! ....or traded this stock to the hilt, well done hoofa.
Relevant info will come via a sp sensitive announcement/s some of the best research done over the years (ABDM probably the most respected) and others have resulted in NOUGHT.
Great to see the product on shelves everywhere, plenty of photo evidence supporting that, lol, hope all that won’t turn out a fizzer like the ACA gig, how soon and how much will that contribute to OBJ s coffers, NOT what we think but actual.
Pay attention to when the instos buy in, perhaps not so much to HC mood/sentiment/hopes.
OBJ Price at posting:
2.7¢ Sentiment: None Disclosure: Held